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Abstract
Background: Thymic stromal derived lymphopoietin (TSLP) is preferentially and highly expressed
in the thymus, but its function in T cell development is not clear.
Results: We report here that TSLP, independently or in combination with IL-7, enhances
thymopoiesis in the murine fetal thymic organ culture (FTOC) model. Furthermore, TSLP
preferentially increases the number and proliferation of the (DN1 and DN2) pro-T progenitor
cells, and FTOC lobes from TSLP receptor-null mice show a decreased number of these cells.
Finally, DN1-DN2 cells expanded with TSLP in vitro are functional T progenitors that are able to
differentiate into mature T cells in fetal or adult thymus organs.
Conclusion: Together, these data suggest that TSLP plays an important role in expansion of
thymocyte progenitors and may be of value for expanding T progenitor cells in vitro.
Background
T cell development in the thymus is characterized by a
series of distinct steps marked by changes in the expres-
sion of cell surface proteins [1]. Hematopoietic stem cells
(HSC) from the fetal liver during early gestation or the
bone marrow later in development, home to the thymus
to begin the process of commitment and maturation to
the T cell lineage [2,3]. The first critical checkpoint occurs
in very early CD4-CD8- double-negative (DN) thymocyte
progenitors, which also lack surface expression of the T
cell receptor (TCR) and are further subdivided into four
stages (DN1-4) based on their surface expression of CD44
and CD25. Successful rearrangement of the genes encod-
ing the TCRβ chain in DN3 cells results in the expression
of a pre-TCR on the cell surface. Subsequent signaling
through the pre-TCR and growth factor receptors induces
cell proliferation and differentiation. The cells mature
into double positive (DP) thymocytes that express both
CD4 and CD8 coreceptors as well as the mature αβ TCR
on the cell surface. A program, termed positive selection,
initiated by TCR-mediated recognition of complexes of
self-peptides and major histocompatibility complex
(MHC) proteins occurs in a minority of DP thymocytes
are further differentiated during the process of positive
and negative selection, resulting in the production of
mature CD4 and CD8 lineage T cells.
T cell development in the thymus is tightly regulated by
thymic microenvironment composed of cytokine-produc-
ing stromal cells. IL-7 produced from thymic stromal cells
plays a critical role in the development of T cells, as mice
lacking IL-7 (IL7-/-) display a marked reduction in thymic
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cause a phenotype similar, but more severe, to that seen in
the absence of IL-7, exhibiting more severely reduced
thymic cellularity and defective T cell maturation [6].
Therefore, IL7-independent signaling pathway via IL-7Rα
is implicated in T cell development.
The IL-7 receptor consists of the common γ chain (γc) and
IL-7Rα. The receptor complex for TSLP, an IL7-like
cytokine, also consists of the IL-7Rα chain and the TSLP
receptor (TSLPR) [7]. Like the γC-mediated signal trans-
duction, signaling through TSLPR also activates the STAT-
5 protein, but independently of the activation of Janus
kinase-3 [8]. Thus, IL-7Rα can signal by TSLP in the
absence of IL-7 and, in the absence of IL-7Rα, both TSLP
and IL-7 signals are blocked.
TSLP is a type 1 cytokine which was originally identified
as a growth factor in the supernatant of a thymic stromal
cell line [9]. However, its effect on thymopoiesis has not
been clearly demonstrated yet. It has been reported that
TSLP promotes the proliferation and differentiation of B-
cell progenitors from fetal liver [10,11]. TSLP can replace
IL-7 in supporting the maturation of B-cells from pro-B
precursors and B cell progenitors fail to develop from
these B cell precursors if no TSLP or IL-7 is present. In
transgenic mice, ectopic expression of TSLP in mice causes
imbalances in lymphopoiesis and myelopoiesis [12].
It has been reported that human TSLP enhances the mat-
uration of CD11c+ dendritic cells to modulate functional
differentiation of CD8+ cells and to support proliferation
of naïve T cells [13,14]. TSLP is also an important factor
involved in allergic airway inflammation [15,16].
Although human TSLP does not directly interact with
human T cells, TSLP is produced by Hassall's corpuscles in
the human thymus, where it instructs thymic dendritic
cells to convert high affinity self-reactive T cells into
CD4+CD25+Foxp3+ regulatory T cells [17]. In TSLP recep-
tor knock-out mice, normal development of T or B cells is
reported [18]. Murine TSLP preferentially enhances the
expansion and survival of CD4+ T cells both in vitro and
in vivo, especially in the absence of IL7-mediated signal-
ing as TSLPR/γc double knockout mice have a greater lym-
phoid defect than γc single KO mice [19]. In murine
neonatal thymus, TSLP produced from medullary thymic
epithelia cells (mTEC) contributes to the expression of
FoxP3 and the maturation of natural regulatory T cells
[20].
We demonstrate here that murine TSLP also plays a role in
regulating early T cell development. In the murine fetal
thymus organ culture (FTOC) model, TSLP alone, or in
combination with IL-7, enhances T cell development.
TSLP preferentially increases the number and prolifera-
tion of the pro-T cells (DN1 and DN2). Furthermore, the
DN1-DN2 cells expanded with TSLP in vitro are func-
tional T progenitor cells that are able to differentiate into
mature T cells in FTOC ex vivo or when injected into mice
in vivo. Together, these data suggest that TSLP is involved
in development and expansion of thymocyte progenitors.
Results
TSLP and IL-7 both enhance thymopoiesis in fetal thymic 
organ culture (FTOC)
Because TSLP and IL-7 share the IL-7 receptor alpha (IL-
7Rα) chain, and IL-7Rα-null mice show more dramatic
defects in thymopoiesis than IL7-null mice, we investi-
gated the importance of TSLP in thymopoiesis. Increasing
doses of TSLP were added to FTOC. Both high doses (100
ng/ml and 30 ng/ml) resulted in a significant increase (2.5
times and 1.8 times, respectively, compared with control)
in total cell number (Fig. 1A and Table 1). When the thy-
mocyte subsets were analyzed, we detected a preferential
increase of DN and SP8 thymocytes, and a relative
decrease in CD4+CD8+ DP cells (Fig. 1B). At higher doses
of TSLP, there was a significant increase in total cell num-
bers of all thymocyte subsets including CD4-CD8- (DN),
CD4+CD8+ (DP), CD4+CD8- (SP4) and CD4-CD8+ (SP8)
thymocytes in TSLP treated FTOCs (Table 1). Interest-
ingly, the DN population was increased even with 10 ng/
ml of TSLP, a concentration at which there was no signif-
icant increase in total thymocytes (Fig. 1C). Therefore, the
DN cells seem to respond more efficiently to TSLP than
DP and SP thymocytes during thymopoiesis.
When the CD3-CD4-CD8- (DN) thymocytes were ana-
lyzed for DN1-DN4 subsets, TSLP enhanced the frequen-
cies and total number of DN1 (CD44+CD25-), DN2
(CD44+CD25+), and DN4 (CD44-CD25-) thymocytes
(Fig. 2A, B and Table 1). Again, even low doses of TSLP
(10 ng/ml) appeared to preferentially expand the DN1,
DN2 and DN4 pro-/pre-T cells. When the TSLPR-/- FTOC
was performed in the presence of recombinant TSLP, nei-
ther total cell numbers nor the numbers of different DN
subsets changed compared with medium control (data
not shown), demonstrating the specificity of TSLP on thy-
mopoiesis.
To further demonstrate that TSLP receptor mediated sign-
aling is important for early thymopoiesis, we analyzed
FTOC fetal thymus lobes from TSLPR-/- mice. Compared
with littermate TSLPR+/+ thymic lobes, the percentages
and total numbers of DN1 and DN2 were reduced (Fig.
2C and 2D). Notably, the DN3 subset was increased in
TSLPR-/- thymic lobes when compared with wild type con-
trol, probably due to compensatory IL-7 signaling. These
results demonstrate an important role for TSLP in thy-
mopoiesis at the early DN stage, which is dispensable dur-
ing mouse development and adaptation.Page 2 of 9
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IL7 in FTOC. Either TSLP or IL-7 in FTOC resulted in sig-
nificantly increased numbers of total thymocytes (Fig.
3A). When the effect of IL-7 on early DN thymocyte pro-
genitors in FTOC was analyzed (Fig. 3B), IL-7 also
increased the number of DN1 and DN2 cells. IL-7 and
TSLP increased DN1 cells by 9.6 and 4.7 fold, respectively;
and DN2 cells by13.7 and 3.2 fold respectively. The com-
bination of IL-7 and TSLP increased the numbers of DN1
and DN2 cells when compared with IL-7 alone. These data
suggest that both TSLP and IL-7 can promote the expan-
sion of early thymocytes.
TSLP enhances early thymopoiesis in mouse fetal thymic organ cultureFigur  1
TSLP enhances early thymopoiesis in mouse fetal thymic organ culture. E15 fetal thymus organs were cultured with different 
doses of TSLP (10, 30 or 100 ng/ml) (A) for 2 weeks. Total thymocytes were harvested and counted. B, TSLP increased the rel-
ative frequencies of CD4-CD8- (DN) and CD4-CD8+ thymocytes in FTOC. C, TSLP preferentially increased the number of DN 
thymocyte cells. Shown are representative data from at least 4 independent experiments. Standard deviation (SD) is shown as 
error bars. *: P < 0.05, * *: P < 0.01, compared with medium control.
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thymocytes in FTOC
The enhancement in the number of DN cells from fetal
thymus by TSLP led us to investigate whether TSLP is
important for the proliferation of these thymocyte sub-
sets. Because the levels of DN cells recoverable from E15
FTOC were too low for the BrdU-labeling assay, we
employed E17 fetal thymic lobes to investigate the prolif-
eration response of DN cells stimulated with TSLP. We
found that the percentage and number of BrdU+ DN1 and
DN2 cells stimulated with TSLP were approximately dou-
bled compared to control (Fig. 4A). The proliferation of
DN4 subset, but not DN3, also was slightly enhanced by
TSLP. In contrast, TSLP did not change the BrdU+percent-
ages of CD4SP and CD8SP cells in FTOC (Fig. 4B). These
data suggest that TSLP specifically increases the prolifera-
tion of early DN thymocyte progenitors.
DN1-DN2 cells expanded by TSLP still have T progenitor 
activity to generate phenotypically mature thymocytes
It is not clear if these DN cells treated and expanded by
TSLP in FTOC in vitro are compromised in their T progen-
itor activity. We assessed the potential of DN1 and DN2
progenitors from TSLP-treated FTOC both in vivo in adult
thymus and in vitro in reconstituted FTOC. Ly5.2+ DN1
thymocyte progenitors sorted from FTOC cultured with or
without TSLP were intrathymically injected into irradiated
Ly5.1+ recipient mice. Two weeks after injection, cells
from thymus were harvested and analyzed. DN1 cells
from mock or TSLP treated FTOC were similar in generat-
ing donor-derived (Ly5.2+) immature or mature thymo-
cytes in mice (Fig. 5A and 5B). Thus, DN1 cells from TSLP-
treated FTOC had the same thymocyte differentiation
capacity as control DN1 cells in adult thymus in vivo, as
determined by CD4 and CD8 expression of donor-derived
thymocytes (Fig. 5C and 5D).
In reconstituted FTOC assay using 2-dG treated E15
thymic lobes, DN2 cells from TSLP-treated FTOC in vitro
also efficiently differentiated into DP and mature SP4+
and SP8+ thymocytes (Fig. 5E). Total cell number and
numbers of SP4, DP and SP8 cells recovered from FTOC
lobes repopulated with TSLP-treated DN2 cells were at
least as high (or higher) as control DN2 cells (Fig. 5F).
These data indicate that DN1 and DN2 cells treated and
expanded in FTOC with TSLP in vitro still possess T pro-
genitor activity. Together, our data suggest that TSLP plays
an important role in expansion of thymocyte progenitors
and may be of value to expand T progenitor cells in vitro.
Discussion
TSLP was initially reported as a cytokine secreted by a
thymic stromal cell line that could replace IL-7 in support-
ing B lymphocyte development [11] and B cell maturation
[9]. It has since been shown to also affect myeloid lineage
cells in both mice and humans. Human TSLP produced by
epithelial cells and keratinocytes, via its interaction with
dendritic cells, has emerged as an important trigger of
Table 1: Effect of TSLP on thymocyte subpopulations in FTOC
Cell # (×103)a Medium TSLP 10 ng/ml TSLP 30 ng/ml TSLP 100 ng/ml
Total 205.7 +/- 73.4b 220 +/- 32.5 356.7 +/- 21.9* 513.3 +/- 72.5**
(1×)c (1×) (1.7×) (2.5×)
CD4-CD8+ 31.0 +/- 9.5 47.3 +/- 8.7 72.3 +/- 15.9* 103.7 +/- 16.9**
(1×) (1.5×) (2.3×) (3.3×)
CD4+CD8+ 138.5 +/- 51.3 124.3 +/- 18.3 169.4 +/- 5.6 260.9 +/- 17.6*
(1×) (1×) (1.2×) (1.9×)
CD4-CD8- 18.7 +/- 8.0 34.1 +/- 5.4* 75.7 +/- 1.2** 96.2 +/- 23.0**
(1×) (1.8×) (4.0×) (5.1×)
CD4+CD8- 17.5 +/- 6.9 14.3 +/- 1.3 39.3 +/- 0.4** 52.3 +/- 18.6*
(1×) (1×) (2.2×) (3.0×)
DN1d 0.6 +/- 0.2 1.6 +/- 0.3* 3.0 +/- 0.5** 5.7 +/- 0.9**
(1×) (2.7×) (5.0×) (9.6×)
DN2 1.9 +/- 1.0 6.4 +/- 1.8* 9.6 +/- 5.3** 19.4 +/- 2.5**
(1×) (3.4×) (5.1×) (10.3×)
DN3 10.6 +/- 5.0 12.0 +/- 3.4 31.2 +/- 8.3 26.7 +/- 16.5
(1×) (1×) (2.9×) (2.5×)
DN4 0.9 +/- 0.4 2.0 +/- 0.4* 6.5 +/- 1.1** 5.5 +/- 1.5**
(1×) (2.2×) (6.9×) (5.9×)
a E15 FTOC with different doses of TSLP were performed for 2 weeks. Thymocytes were harvested and analyzed by FACS. The number (×103) of 
thymocyte subsets recovered from each FTOC lobe is shown. The data is a summary of 4 independent experiments.
b Average number +/- SD;
c Fold over medium control.
d Thymocytes that were negative for expression of CD3/CD4/CD8 were analyzed for DN1 to DN4 subpopulations based on the expression of 
CD44 and CD25. * p < 0.05; ** p < 0.01, compared with medium control.Page 4 of 9
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expansion [13,14,21]. In addition, TSLP has been recently
reported to modulate mature CD4+ T cell proliferation
and survival [19]. However, Sims et al. [22] have reported
that addition of TSLP to purified CD4-8- DN thymocytes
in vitro results in no change in cell proliferation. This may
be due to lack of other co-factors that are present in the
FTOC culture. Interestingly, when combined with IL-1,
TSLP can lead to a significant expansion of these purified
DN cells in vitro. We report here that TSLP enhances thy-
mopoiesis, and preferentially increases the number and
proliferation of the pro-/pre-T (DN1, DN2 and DN4) cells
in FTOC assays. In addition to increasing the number of
thymocytes (Table 1), TSLP may also promote differentia-
tion of thymocytes as TSLP increased both the numbers
and percentages of CD8SP and CD4SP cells (Fig. 1B) but
not their proliferation (Fig. 4B). Therefore, TSLP appears
to affect myeloid cells, B cells, and T cells at various stages
of development.
It is of interest to note that IL-7 and TSLP play similar but
non-overlapping roles in thymopoiesis. While IL-7 uses
the IL7Rα/γc receptor complex, TSLP signals via a receptor
comprising the IL-7Rα and a distinctive subunit, TSLPR
[7,23]. IL-7 has been shown to support the growth of DN
and CD4-CD8+ subpopulations in FTOC system [24], but
DN1 and DN2 cells are preferentially increased by TSLP in FTOC and decreased in TSLPR-/- FTOCFigure 2
DN1 and DN2 cells are preferentially increased by TSLP in FTOC and decreased in TSLPR-/- FTOC. A and B, FTOCs using WT 
E15 thymic lobes were performed with different doses of TSLP (10, 30 or 100 ng/ml) for 2 weeks. Thymocytes that were neg-
ative for expression of CD3/CD4/CD8 were further analyzed for DN subpopulation based on the expression of CD44 and 
CD25. Shown are representative data from at least 4 independent experiments. SD is shown as error bars. *: P < 0.05, * *: P < 
0.01, compared with medium control. C and D, FTOCs from littermate TSLPR+/+ or TSLPR-/-embryos were cultured for 2 
weeks and DN cells were analyzed. The data is a summary of 3 independent experiments. Error bars indicate SD, * P < 0.05, * 
*: P < 0.01, compared with TSLPR+/+ control lobes.
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4, another cytokine which uses the common cytokine
receptor γc [25], can also block the development of
CD4+CD8+ thymocytes in FTOC [26]. In our study, TSLP
increases the cell number of all subpopulations (Table 1),
but preferentially enhances proliferation of DN1, DN2,
and DN4 cells (Fig. 3). Based on the expression of CD24
and CD117, DN1 cells can be further subdivided into 5
subsets [27]. TSLP may affect the proliferation and/or dif-
ferentiation of some or all these subsets. Unfortunately,
we have been unable to obtain enough cells for a thor-
ough analysis of the responsiveness of these DN1 subsets
to TSLP in FTOC. These data suggest that TSLP enhances T
progenitor cell expansion and supports their succeeding
thymocyte differentiation pathway.
TSLPR-deficient adult mice have shown no significant
developmental abnormality in T cells and B cells [18,19].
Studies in TSLPR/γc DKO mice have indicated a role for
TSLP in CD4+ T cell homeostasis [19]. Similarly, TSLP is
implicated in the induction of splenic B cells from studies
with TSLPR/Jak3-/- DKO mice [18]. These findings suggest
the TSLP has an overlapping role with IL-7 (and possibly
other cytokines) in controlling lymphopoiesis. Interest-
ingly, TSLP seems to promote B lymphocyte production
from fetal liver-, but not adult BM-, derived pro-B cells
[28]. The normal phenotype of T and B cells in TSLPR KO
mice suggests that TSLP may be involved in fetal thy-
mopoiesis, and other cytokines such as IL-7 may play a
compensatory or adaptive role in T/B cell development
during development of TSLPR-null mice [4,6,29].
Methods
Animals
B6/Ly5.1 and B6/Ly5.2 mice were purchased from the
Jackson Laboratory and TSLP-R-deficient mice were pro-
vided by Dr. J. Ihle [18] and backcrossed to B6/Ly5.2
background for more than 4 generations. All mice were
TSLP and IL-7 both enhances early T progenitor cells and thymopoiesis in mouse fetal thymic organ cultureFigure 3
TSLP and IL-7 both enhances early T progenitor cells and thymopoiesis in mouse fetal thymic organ culture. E15 fetal thymus 
organs were cultured with either TSLP (30 ng/ml) and/or IL-7 (100 ng/ml) for 2 weeks. Total thymocytes were harvested and 
counted (A). Thymocytes that were negative for expression of CD3/CD4/CD8 were further analyzed for DN subpopulation 
based on the expression of CD44 and CD25 (B). The data is a summary of 2 independent experiments. Standard deviation 
(SD) is shown as error bars. *: P < 0.05, * *: P < 0.01, compared with medium control.
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BMC Immunology 2007, 8:11 http://www.biomedcentral.com/1471-2172/8/11housed in a sterile animal facility at the University of
North Carolina at Chapel Hill [30]. Mice were mated for
16 h and fetuses were removed from pregnant females at
various days of gestation (plug date = day 0).
Media and reagents
FTOC medium contains RPMI 1640 (GIBCO BRL) sup-
plemented with L-glutamine, 10 % FBS, 50 μM 2-ME, 2
mM L-glutamine, 1 % nonessential amino acid (GIBCO
BRL), 10 mM HEPES, 1 mM sodium pyruvate solution
(GIBCO BRL), 100 U/ml Penicillin and 100 mg/ml Strep-
tomycin. 2-deoxyguanosine (2-dG) was purchased from
Sigma-Aldrich (St. Louis, MO). Recombinant mouse TSLP
was obtained from R&D Systems (Minneapolis, MN) and
recombinant mouse IL-7 from PeproTech INC (Rocky
Hill, NJ).
Mouse fetal thymus organ culture (FTOC)
Thymic lobes from day 15 or day 17 embryos were cul-
tured on the membranes directly with adding cytokines to
the medium as described [31]. The lobes were cultured at
37°C in 5 % CO2 for indicated period, being re-fed with
fresh FTOC medium plus cytokines every three days. For
hanging drop-mediated transfer and organ culture of
sorted cells, thymic lobes from day 15 embryos were cul-
tured for 5 days in the presence of 1.35 mM 2-dG. The
lobes were washed and co-cultured with sorted DN2 cells
(1 × 103/well) in hanging drops (40 μl/well) in Terasaki
plates for 48 hours at 37°C. Lobes were rinsed with cul-
ture medium and organ culture on membranes for indi-
cated period.
FACS analysis
Cells isolated from fresh or cultured fetal thymic lobes
were prepared as described. Monoclonal antibodies to
CD3-ε, CD4, CD8, CD44, CD25, CD45.1, CD45.2, were
obtained from BD Pharmingen (San Jose, CA), or Caltag
(South San Francisco, CA).
BrdU analysis was performed by adding 25 μM BrdU
(Sigma, St. Louis, MO) to the culture medium for 4 h
before harvesting thymic lobes. Following extracellular
staining, cells were fixed, permeabilized, and then stained
with anti-BrdU-FITC (Becton Dickinson, Mountain View,
CA). Events were collected on a FACScalibur (Becton
Dickinson) and analysis was performed by using Summit
v3.1 program [32].
Intrathymic injection
Two to three months old recipient B6/Ly5.1 animals were
administered with sterile pH2.0 water supplemented with
neomycin sulfate. Sub-lethal irradiation of animals (500
rads) was administered with a Cesium source irradiator.
The Institutional Animal Care and Use Committee
approved all experiments. E15 thymic lobes were stimu-
lated with TSLP (30 ng/ml) for 2 weeks, DN1 and DN2
cells were sorted by FACSVantage (Becton Dickinson).
Sorted DN1 cells (4 × 103/mouse) were injected into thy-
mus of irradiated recipient mice with carrier cells (recipi-
ent type thymocytes: 1 × 105 cells/mouse). Two weeks
after injection, mice were sacrificed and cells from thymus
and spleen were harvested and analyzed by flow cytome-
try.
TSLP increases proliferation of DN1 and DN2 thymocytes in FTOCigure 4
TSLP increases proliferation of DN1 and DN2 thymocytes in 
FTOC. E17 FTOCs were cultured with or without TSLP (30 
ng/ml) for 48 hours, and BrdU was added for the last 4 hours 
before analysis. (A) Thymocytes from each FTOC lobe were 
harvested, stained for CD44, CD25, CD3, CD4, CD8 and 
BrdU. Thymocytes that were negative for expression of 
CD3, CD4 and CD8 were analyzed for DN subpopulations 
and relative BrdU incorporation. (B) The same thymocytes 
were analyzed for BrdU incorporation in CD3+CD4+ or 
CD3+CD8+ cells. The data is representative of two inde-
pendent experiments. *, indicates p < 0.05; **, p < 0.01.
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DN1 and DN2 cells from TSLP-treated FTOC have T progenitor activity to generate phenotypically mature thymocytes. DN1 
and DN2 cells from FTOC lobes (Ly5.2) cultured with TSLP (30 ng/ml) or medium control were purified. Sorted DN1 cells (4 
× 103/mouse) were injected directly into thymi of irradiated (500 rad) Ly5.1 recipient mice with fresh carrier cells (Ly5.1+ thy-
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DN2 cells (1 × 103/well) were seeded into 2-dG treated E15 thymic lobes by hanging drop culture, and cultured as FTOC for 
2 weeks. Thymocytes were harvested and analyzed as above. The data is representative of two independent experiments. Bars 
indicate SD, * P < 0.05, compared with medium control.
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